Compare iShares MSCI Japan ETF (EWJ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Japan ETF trades at $94.51 (market cap $23.22B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: iShares MSCI Japan ETF is far larger — about 4.6× Travere Therapeutics Inc. Common Stock's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 57 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EWJ | TVTX | |
|---|---|---|
Market Cap | $23.22B | $5.02B |
Volume | 5,587,717 | 2,060,842 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $67.52 |
52-Week Low | $79.49 | $26.79 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, a US-listed ETF tracking Japanese equities, trades at $97.32 with no change on the day. Technical indicators show a bullish overall signal, with moving averages supporting an uptrend while oscillators remain neutral. Recent news highlights Japan's monetary policy shifts and international ETF outperformance, with the Nikkei 225 experiencing volatility amid rising bond yields and fiscal stimulus debates.
The outlook for EWJ is cautiously optimistic, driven by Japan's economic stimulus and potential yen strength, but risks include BOJ policy uncertainty and global yield pressures. Investors may find opportunity in Japan's AI and semiconductor exposure, though currency fluctuations and fiscal challenges pose headwinds for sustained gains.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
